Alnylam Pharmaceuticals Share Price Today
(NASDAQ: ALNY)

Name: Alnylam Pharmaceuticals Share Price Today (NASDAQ: ALNY) - Alnylam Pharmaceuticals Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Alnylam Pharmaceuticals share price is $250.59 & ₹21,732.67 as on 22 Feb 2025, 2.30 'hrs' IST

$250.59

▲

-0.41

(-0.16%)

Market is closed - opens 8 PM, 24 Feb 2025

View live Alnylam Pharmaceuticals share price in Dollar and Rupees. Guide to invest in Alnylam Pharmaceuticals stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Alnylam Pharmaceuticals, along with analyst recommendations, forecasts, and comprehensive financials.

Alnylam Pharmaceuticals share price movements

Today's Low: $246.85
Today's High: $253.15
$250.59
1.49%
Downside
Day's Volatility :2.49%
Upside
1.01%
52 Weeks Low: $141.98
52 Weeks High: $304.39
$250.59
43.34%
Downside
52 Weeks Volatility :53.36%
Upside
17.67%

Alnylam Pharmaceuticals (ALNY) Returns

Period	Alnylam Pharmaceuticals, Inc.	Sector (Health Care)	Index (Russel 2000)
3 Months	-0.16%	1.6%	0.0%
6 Months	-6.89%	-5.8%	0.0%
1 Year	57.94%	-1.0%	0.0%
3 Years	63.9%	15.7%	-9.0%

Alnylam Pharmaceuticals (ALNY) Key Statistics

in dollars & INR

Previous Close	$251.0
Open	$253.7
Today's High	$253.15
Today's Low	$246.8535
Market Capitalization	$32.5B
Today's Volume	$645.4K
52 Week High	$304.39
52 Week Low	$141.975
Revenue TTM	$2.2B
EBITDA	$-120.2M
Earnings Per Share (EPS)	$-2.18
Profit Margin	-12.37%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-1500.66%

How to invest in Alnylam Pharmaceuticals Stock (ALNY) from India?

It is very easy for Indian residents to invest directly in Alnylam Pharmaceuticals from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Alnylam Pharmaceuticals stock in both Indian Rupees (INR) and US Dollars (USD). Search for Alnylam Pharmaceuticals or ALNY on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Alnylam Pharmaceuticals or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Alnylam Pharmaceuticals shares which would translate to 0.003 fractional shares of Alnylam Pharmaceuticals as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Alnylam Pharmaceuticals, in just a few clicks!

Returns in Alnylam Pharmaceuticals (ALNY) for Indian investors in Rupees

The Alnylam Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Alnylam Pharmaceuticals investment value today

Current value as on today

₹1,62,591

Returns

₹62,591

(+62.59%)

Returns from Alnylam Pharmaceuticals Stock

₹57,942 (+57.94%)

Dollar Returns

₹4,649 (+4.65%)

Indian investors sentiment towards Alnylam Pharmaceuticals (ALNY)

96%

Period: Jan 23, 2025 to Feb 22, 2025. Change in 30 Days versus previous period

Search interest for Alnylam Pharmaceuticals Stock from India on INDmoney has increased by 96% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Alnylam Pharmaceuticals

Capital World Investors
12.84%
FMR Inc
11.35%
Vanguard Group Inc
9.85%
BlackRock Inc
7.51%
Capital Research Global Investors
5.39%
Regeneron Pharmaceuticals Inc
3.44%

Analyst Recommendation on Alnylam Pharmaceuticals

Buy

70%Buy

29%Hold

0%Sell

Based on 34 Wall street analysts offering stock ratings for Alnylam Pharmaceuticals(by analysts ranked 0 to 5 stars)

Based on 34 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Alnylam Pharmaceuticals Stock (ALNY)

What analysts predicted

Upside of 20.23%

Target:

$301.27

Current:

$250.59

Insights on Alnylam Pharmaceuticals Stock (Ticker Symbol: ALNY)

Price Movement
In the last 1 year, ALNY stock has moved up by 59.0%
Increasing Revenue
Alnylam Pharmaceuticals, Inc. has seen a positive trend in its revenue over the last two quarters. In the last quarter, the revenue increased from $500.91 million to $593.16 million, resulting in an average growth of 15.6% per quarter.
Increasing Net Profit
Alnylam Pharmaceuticals, Inc. has shown an improvement in its net profit over the last two quarters. The net profit increased from -$111.57 million to -$83.76 million, representing an average increase of 33.2% per quarter.

ALNY Alnylam Pharmaceuticals Financials in INR & Dollars

	FY19	Y/Y Change
Revenue	$219.8M	↑ 193.36%
Net Income	$-886.1M	↑ 16.37%
Net Profit Margin	-403.24%	↑ 613.34%

	FY20	Y/Y Change
Revenue	$492.9M	↑ 124.28%
Net Income	$-858.3M	↓ 3.14%
Net Profit Margin	-174.15%	↑ 229.09%

	FY21	Y/Y Change
Revenue	$844.3M	↑ 71.31%
Net Income	$-852.8M	↓ 0.64%
Net Profit Margin	-101.01%	↑ 73.14%

	FY22	Y/Y Change
Revenue	$1.0B	↑ 22.88%
Net Income	$-1.1B	↑ 32.64%
Net Profit Margin	-109.04%	↓ 8.03%

	FY23	Y/Y Change
Revenue	$1.8B	↑ 76.23%
Net Income	$-440.2M	↓ 61.08%
Net Profit Margin	-24.08%	↑ 84.96%

	FY24	Y/Y Change
Revenue	$2.2B	↑ 22.97%
Net Income	$-278.2M	↓ 36.82%
Net Profit Margin	-12.37%	↑ 11.71%

	Q3 FY23	Q/Q Change
Revenue	$750.5M	↑ 135.46%
Net Income	$147.8M	↓ 153.53%
Net Profit Margin	19.69%	↑ 106.28%

	Q4 FY23	Q/Q Change
Revenue	$439.7M	↓ 41.41%
Net Income	$-137.9M	↓ 193.31%
Net Profit Margin	-31.35%	↓ 51.04%

	Q1 FY24	Q/Q Change
Revenue	$494.3M	↑ 12.42%
Net Income	$-65.9M	↓ 52.18%
Net Profit Margin	-13.34%	↑ 18.01%

	Q2 FY24	Q/Q Change
Revenue	$659.8M	↑ 33.48%
Net Income	$-16.9M	↓ 74.39%
Net Profit Margin	-2.56%	↑ 10.78%

	Q3 FY24	Q/Q Change
Revenue	$500.9M	↓ 24.08%
Net Income	$-111.6M	↑ 560.61%
Net Profit Margin	-22.27%	↓ 19.71%

	Q4 FY24	Q/Q Change
Revenue	$593.2M	↑ 18.42%
Net Income	$-83.8M	↓ 24.92%
Net Profit Margin	-14.12%	↑ 8.15%

	FY19	Y/Y Change
Profit	$194.7M	↑ 166.31%

	FY20	Y/Y Change
Profit	$414.8M	↑ 113.06%

	FY21	Y/Y Change
Profit	$704.1M	↑ 69.75%

	FY22	Y/Y Change
Profit	$868.6M	↑ 23.36%

	FY23	Y/Y Change
Profit	$1.5B	↑ 74.75%

	FY24	Y/Y Change
Profit	$1.9B	↑ 26.81%

	Q3 FY23	Q/Q Change
Profit	$666.2M	↑ 185.46%

	Q4 FY23	Q/Q Change
Profit	$353.9M	↓ 46.89%

	Q1 FY24	Q/Q Change
Profit	$428.4M	↑ 21.05%

	Q2 FY24	Q/Q Change
Profit	$591.2M	↑ 38.0%

	Q3 FY24	Q/Q Change
Profit	$415.0M	↓ 29.8%

	Q4 FY24	Q/Q Change
Profit	$490.3M	↑ 18.15%

	FY19	Y/Y Change
Operating Cash Flow	$-278.4M	↓ 50.51%
Investing Cash Flow	$-417.7M	↓ 253.03%
Financing Cash Flow	$823.2M	↑ 1157.35%

	FY20	Y/Y Change
Operating Cash Flow	$-615.0M	↑ 120.87%
Investing Cash Flow	$-435.5M	↑ 4.27%
Financing Cash Flow	$995.0M	↑ 20.87%

	FY21	Y/Y Change
Operating Cash Flow	$-641.7M	↑ 4.35%
Investing Cash Flow	$-273.3M	↓ 37.25%
Financing Cash Flow	$1.2B	↑ 25.34%

	FY22	Y/Y Change
Operating Cash Flow	$-541.3M	↓ 15.65%
Investing Cash Flow	$169.4M	↓ 161.97%
Financing Cash Flow	$425.8M	↓ 65.86%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$359.4M	↓ 709.32%
Investing Cash Flow	$-10.8M	↑ 23.54%
Financing Cash Flow	$33.1M	↓ 37.94%

Alnylam Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Alnylam Pharmaceuticals is currently in a neutral trading position according to technical analysis indicators.

Alnylam Pharmaceuticals (ALNY) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Alnylam Pharmaceuticals, Inc.	-10.11%	-6.89%	57.94%	63.9%	110.07%
Biontech Se	1.58%	37.14%	28.33%	-22.1%	258.88%
Regeneron Pharmaceuticals, Inc.	3.63%	-41.61%	-29.21%	14.85%	58.32%
Vertex Pharmaceuticals Incorporated	10.15%	0.33%	11.71%	110.31%	110.54%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.59	-15.01	-0.03	NA	0.52
Biontech Se	160.8	NA	0.04	-3.29	-0.02	-0.01	NA	79.73
Regeneron Pharmaceuticals, Inc.	18.16	18.16	1.01	43.09	0.16	0.07	0.01	273.57
Vertex Pharmaceuticals Incorporated	32.84	NA	1.3	18.11	-0.03	0.13	NA	63.87

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Alnylam Pharmaceuticals, Inc.	Buy	$32.5B	110.07%	NA	-12.37%
Biontech Se	Buy	$28.3B	258.88%	160.8	-15.36%
Regeneron Pharmaceuticals, Inc.	Buy	$76.1B	58.32%	18.16	31.07%
Vertex Pharmaceuticals Incorporated	Buy	$123.3B	110.54%	32.84	-4.86%

Alnylam Pharmaceuticals Dividend announcements

Alnylam Pharmaceuticals Earnings
Alnylam Pharmaceuticals’s price-to-earnings ratio stands at None
Read More

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clinical trial for hemophilia; cemdisiran that is in phase III clinical trial for Myasthenia Gravis and paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and ALN-6400, which is in phase I clinical trial for bleeding disorders. In addition, the company is also developing Zilebesiran, which is in phase II clinical trial for hypertension; Rapirosiran that is in phase II clinical trial for Metabolic dysfunction-associated steatohepatitis; ALN-4324, which is in phase I clinical trial for type 2 diabetes mellitus; ALN-PNP that is in phase I clinical trial for non-alcoholic fatty liver disease; ALN-APOC3, which is in phase I clinical trial for dyslipidemia; Mivelsiran that is in phase II clinical trial for cerebral amyloid angiopathy, and phase I clinical trial for Alzheimer's disease; and ALN-HTT02 that is in phase I clinical trial for Huntington's disease. Further, it develops ALN-SOD, which is in phase II clinical trial for SOD1 Amyotrophic lateral sclerosis; Elebsiran that is in phase II clinical trial for Hepatitis B and D virus infections; ALN-BCAT that is in phase I clinical trial for hepatocellular carcinoma; and ALN-ANG3. It has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Regeneron Pharmaceuticals, Inc.; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Organization	Alnylam Pharmaceuticals
Employees	2230
CEO	Dr. Yvonne L. Greenstreet M.B.A., MBChB
Industry	Health Technology

Management People of Alnylam Pharmaceuticals

Name	Title
Dr. Yvonne L. Greenstreet M.B.A., MBChB	CEO & Director
Mr. Jeffrey V. Poulton M.B.A.	CFO & Executive VP
Dr. Akshay K. Vaishnaw M.D., Ph.D.	Chief Innovation Officer & Member of the Scientific Advisory Board
Dr. Pushkal P. Garg M.D.	Chief Medical Officer
Mr. Tolga Tanguler M.B.A.	Executive VP & Chief Commercial Officer
Mr. Timothy J. Maines	Chief Technical Operations & Quality Officer
Dr. Kevin Joseph Fitzgerald Ph.D.	Senior VP, Head of Research & Chief Scientific Officer
Mr. Piyush Sharma J.D.	Chief Ethics & Compliance Officer
Mr. Robert W. Hesslein Esq., J.D.	Chief Legal Officer & Corporate Secretary
Ms. Christine Regan Lindenboom	Chief Corporate Communications Officer

Important FAQs about investing in ALNY Stock from India :

What is Alnylam Pharmaceuticals share price today?

Alnylam Pharmaceuticals share price today stands at $250.59, Open: $253.70 ; Previous Close: $251.00 ; High: $253.15 ; Low: $246.85 ; 52 Week High: $304.39 ; 52 Week Low: $141.98.

The stock opens at $253.70, after a previous close of $251.00. The stock reached a daily high of $253.15 and a low of $246.85, with a 52-week high of $304.39 and a 52-week low of $141.98.

Can Indians buy Alnylam Pharmaceuticals shares?

Yes, Indians can invest in the Alnylam Pharmaceuticals (ALNY) from India.

With INDmoney, you can buy Alnylam Pharmaceuticals at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Alnylam Pharmaceuticals at zero transaction cost.

How can I buy Alnylam Pharmaceuticals shares from India?

It is very easy to buy Alnylam Pharmaceuticals from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Alnylam Pharmaceuticals (ALNY) be purchased?

Yes, you can buy fractional shares of Alnylam Pharmaceuticals with INDmoney app.

What are the documents required to start investing in Alnylam Pharmaceuticals stocks?

To start investing in Alnylam Pharmaceuticals, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.